Investigation announced for Long-Term Investors in NASDAQ: SESN shares over possible Wrongdoing at Sesen Bio, Inc.

An investigation was announced concerning possible breaches of fiduciary duties by certain directors of Sesen Bio, Inc..

Investors who are current long term investors in Sesen Bio, Inc. (NASDAQ: SESN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: SESN stocks follows a lawsuit filed against Sesen Bio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: SESN stocks, concerns whether certain Sesen Bio directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that, the Defendants failed to disclose to investors, that Sesen Bio’s clinical trial for Vicineum had more than 2,000 violations of trial protocol, including 215 classified as “major”, that three of Sesen Bio’s clinical investigators were found guilty of “serious noncompliance,” including “back-dating data”, that Sesen Bio had submitted the tainted data in connection with the BLA for Vicineum, that Sesen Bio’s clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury, that, as a result of the foregoing, the Company’s BLA for Vicineum was not likely to be approved, that, as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Sesen Bio, Inc. (NASDAQ: SESN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.